Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPADINE
2016-000281-39Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic neuropathy and diabetic polyneuropathy (DPN) comparing Olodanrigan with Placebo (2 arms). Primary endpoint: Change in weekly mean 24-hour average pain score from baseline to Week 12. Started Nov 2017; status: completed.
02
Drugs
olodanrigan
03
Conditions
diabetic neuropathydiabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2016-000281-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000281-39.